Wilms Tumor Suppressor, WT1, Cooperates with MicroRNA-26a and MicroRNA-101 to Suppress Translation of the Polycomb Protein, EZH2, in Mesenchymal Stem Cells*

  1. Paul R. Goodyer,§,1
  1. From the Department of Human Genetics, McGill University, Montréal, Québec H3A 1B1,
  2. the Department of Experimental Medicine, McGill University, Montreal, Québec H3A 1A3, and
  3. the §Department of Pediatrics, Research Institute of the McGill University Health Center, Montréal, Québec H4A 3J1, Canada
  1. 1 Recipient of a James McGill Research Chair. To whom correspondence should be addressed: Depts. of Human Genetics and Pediatrics, Montreal Children's Hospital Research Institute, 1001 Décarie Blvd., Bloc E, Lab E012371, Montreal, QC H4A 3J1, Canada. Tel.: 514-412-4400 (ext. 22584); Fax: 514-412-4478; E-mail: paul.goodyer{at}mcgill.ca.

Abstract

Hereditary forms of Wilms arise from developmentally arrested clones of renal progenitor cells with biallelic mutations of WT1; recently, it has been found that Wilms tumors may also be associated with biallelic mutations in DICER1 or DROSHA, crucial for miRNA biogenesis. We have previously shown that a critical role for WT1 during normal nephrogenesis is to suppress transcription of the Polycomb group protein, EZH2, thereby de-repressing genes in the differentiation cascade. Here we show that WT1 also suppresses translation of EZH2. All major WT1 isoforms induce an array of miRNAs, which target the 3′ UTR of EZH2 and other Polycomb-associated transcripts. We show that the WT1(+KTS) isoform binds to the 5′ UTR of EZH2 and interacts directly with the miRNA-containing RISC to enhance post-transcriptional inhibition. These observations suggest a novel mechanism through which WT1 regulates the transition from resting stem cell to activated progenitor cell during nephrogenesis. Our findings also offer a plausible explanation for the fact that Wilms tumors can arise either from loss of WT1 or loss of miRNA processing enzymes.

Footnotes

  • * This work was supported in part by Operating Grant MOP-119571 from the Canadian Institutes of Health Research (CIHR) and an infrastructure support grant to the McGill University Health Center Research Institute from the Fonds de la Recherche en Santé du Québec (FRSQ). The authors declare that they have no conflicts of interest with the contents of this article.

  • Received July 24, 2015.
  • Revision received December 9, 2015.
Table of Contents

This Article

  1. The Journal of Biological Chemistry 291, 3785-3795.
  1. All Versions of this Article:
    1. M115.678029v1
    2. 291/8/3785 (most recent)

Classifications

Article Usage Stats

Submit your work to JBC.

You'll be in good company.